149 related articles for article (PubMed ID: 22644973)
1. Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Patel S; Le A; Gascon S
Am J Health Syst Pharm; 2012 Jun; 69(12):1015-6. PubMed ID: 22644973
[No Abstract] [Full Text] [Related]
2. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
3. The status of allopurinol in the management of tumor lysis syndrome: a clinical review.
Hagemeister F; Huen A
Cancer J; 2005; 11 Suppl 1():S1-10. PubMed ID: 15835720
[No Abstract] [Full Text] [Related]
4. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Holdsworth MT; Nguyen P
Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
[TBL] [Abstract][Full Text] [Related]
5. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Cairo MS; Thompson S; Tangirala K; Eaddy MT
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
[TBL] [Abstract][Full Text] [Related]
6. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
[TBL] [Abstract][Full Text] [Related]
7. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
9. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic considerations in the management of acute tumor lysis syndrome.
Farber MS
Semin Oncol; 2001 Apr; 28(2 Suppl 5):19-22. PubMed ID: 11343274
[No Abstract] [Full Text] [Related]
11. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
13. Rasburicase: future directions in tumor lysis management.
Hochberg J; Cairo MS
Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
[TBL] [Abstract][Full Text] [Related]
14. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Jeha S; Pui CH
Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
[TBL] [Abstract][Full Text] [Related]
15. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Abousaud MI; Rush MC; Rockey M
J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
[TBL] [Abstract][Full Text] [Related]
16. Managing malignancy-associated hyperuricemia with rasburicase.
Cheson BD; Dutcher BS
J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
18. [The current status of the treatment of tumor lysis syndrome--the role of rasburicase (Fasturtec)].
Urbieta M
Arch Pediatr; 2005 Oct; 12 Spec No 1():8-12. PubMed ID: 17076004
[No Abstract] [Full Text] [Related]
19. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
20. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]